Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
FDF
0
Europe
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
A (R)-Zanubrutinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of (R)-Zanubrutinib, including repackagers and relabelers. The FDA regulates (R)-Zanubrutinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. (R)-Zanubrutinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of (R)-Zanubrutinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A (R)-Zanubrutinib supplier is an individual or a company that provides (R)-Zanubrutinib active pharmaceutical ingredient (API) or (R)-Zanubrutinib finished formulations upon request. The (R)-Zanubrutinib suppliers may include (R)-Zanubrutinib API manufacturers, exporters, distributors and traders.
click here to find a list of (R)-Zanubrutinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A (R)-Zanubrutinib DMF (Drug Master File) is a document detailing the whole manufacturing process of (R)-Zanubrutinib active pharmaceutical ingredient (API) in detail. Different forms of (R)-Zanubrutinib DMFs exist exist since differing nations have different regulations, such as (R)-Zanubrutinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A (R)-Zanubrutinib DMF submitted to regulatory agencies in the US is known as a USDMF. (R)-Zanubrutinib USDMF includes data on (R)-Zanubrutinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The (R)-Zanubrutinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of (R)-Zanubrutinib suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a (R)-Zanubrutinib Drug Master File in Korea ((R)-Zanubrutinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of (R)-Zanubrutinib. The MFDS reviews the (R)-Zanubrutinib KDMF as part of the drug registration process and uses the information provided in the (R)-Zanubrutinib KDMF to evaluate the safety and efficacy of the drug.
After submitting a (R)-Zanubrutinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their (R)-Zanubrutinib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of (R)-Zanubrutinib suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing (R)-Zanubrutinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for (R)-Zanubrutinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture (R)-Zanubrutinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain (R)-Zanubrutinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a (R)-Zanubrutinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of (R)-Zanubrutinib suppliers with NDC on PharmaCompass.
(R)-Zanubrutinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of (R)-Zanubrutinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right (R)-Zanubrutinib GMP manufacturer or (R)-Zanubrutinib GMP API supplier for your needs.
A (R)-Zanubrutinib CoA (Certificate of Analysis) is a formal document that attests to (R)-Zanubrutinib's compliance with (R)-Zanubrutinib specifications and serves as a tool for batch-level quality control.
(R)-Zanubrutinib CoA mostly includes findings from lab analyses of a specific batch. For each (R)-Zanubrutinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
(R)-Zanubrutinib may be tested according to a variety of international standards, such as European Pharmacopoeia ((R)-Zanubrutinib EP), (R)-Zanubrutinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia ((R)-Zanubrutinib USP).
LOOKING FOR A SUPPLIER?
